We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » UK Group Pushes for HTAs to Review More Biosimilars
UK Group Pushes for HTAs to Review More Biosimilars
January 15, 2013
The UK’s National Institute for Health and Clinical Excellence (NICE) and other health technology assessment (HTA) bodies should fully assess biosimilars for clinical and cost effectiveness, the Association for British Pharmaceutical Industries (ABPI) says.